CNBC’s Meg Tirrell takes a look at the treatments and experimental medicines President Trump is receiving for what experts are saying is a ‘severe’ case of Covid-19. For access to live and exclusive video from CNBC subscribe to CNBC PRO:
Experts in the medical community have mixed opinions about the decision to treat President Donald Trump’s coronavirus diagnosis with an experimental antibody cocktail from Regeneron Pharmaceuticals, CNBC’s Christina Farr and Kevin Stankiewicz reported.
“This was a wholly appropriate decision to give him active therapy, and then it just became a choice of which therapy,” former Food and Drug Administration commissioner Dr. Scott Gottlieb told CNBC.
Other doctors had concerns about the president receiving preferential treatment. The antibody drug has not yet been approved by federal regulators and there’s still limited data on its impact.
Trump’s physician, Dr. Sean Conley, said in a White House memo that the president was given Regeneron’s treatment “as a precautionary measure.”
Regeneron’s REGN-COV2 treatment is a shot of lab-generated antibodies that aims boost the immune system’s defenses by mimicking how the body would defend against a foreign invader like the coronavirus.
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:
Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:
For info on the best credit cards go to CNBC Select:
#CNBC
#CNBCTV